Nobel laureate's AI drug startup in talks for funding at up to $50 billion

Isomorphic Labs, an AI-powered drug discovery company under Alphabet led by 2024 Nobel Chemistry Prize winner Demis Hassabis, is now in early talks for a new funding round. The company focuses on using AI to speed up new drug development.\n\nIn May, Isomorphic Labs completed its Series B round, raising $2.1 billion from its parent company and other investors. According to Bloomberg, the new round could value the firm at at least $40 billion, possibly up to $50 billion.\n\nAI in biopharmaceuticals is still at an early stage. While many companies have explored it at a conceptual level, moving from clinical trials to a final market launch still takes much more work.